Breakthrough Discovery: Identifying Seizure Risk in Alzheimer’s Patients

A team of researchers from UCLA Health has made a significant discovery that could revolutionize the monitoring and treatment of Alzheimer’s disease. By identifying specific changes in brain rhythms, they suggest a method to detect seizure activity in patients suffering from Alzheimer’s, offering new hope for early intervention.

Understanding the Discovery

The study, featured in the journal Brain Communications, is a continuation of the groundbreaking work by UCLA neurologist and senior author Dr. Keith Vossel. Dr. Vossel first linked silent epileptic activity to cognitive decline in Alzheimer’s, opening a new field of inquiry.

Research Methodology

Building on Dr. Vossel’s previous research, the UCLA team, along with colleagues from UCSF, conducted a comprehensive analysis of MEG (magnetoencephalography) and EEG (electroencephalography) recordings. They focused on high-frequency oscillations (HFOs) – brief bursts of rhythmic brain activity indicative of epilepsy. These oscillations were detected in patients with Alzheimer’s and compared to healthy individuals.

Key Findings

The research found HFOs occur at significantly higher rates (two to three times) in Alzheimer’s patients compared to healthy subjects. Importantly, MEG proved to be more effective than EEG for detecting these signals, due to its better signal-to-noise ratio.

Another notable finding was the asymmetry of HFOs in Alzheimer’s patients. They appeared more frequently on the right side of the brain in patients with epileptic activity.

The Role of Medication

The study also evaluated the impact of antiseizure medication, specifically levetiracetam. Data from Dr. Vossel’s Phase 2a clinical trial showed that HFOs coinciding with epileptic spikes were suppressed by levetiracetam, indicating its potential as a treatment for managing these seizures.

Encouragingly, MEG screening for HFOs takes just 10 minutes, offering a practical and efficient way to identify Alzheimer’s patients at higher risk of epileptic activity.”

Dr. Keith Vossel, UCLA neurologist and senior author

Implications for Patient Care

The findings suggest that HFOs could serve as a critical biomarker for identifying Alzheimer’s patients at increased risk of seizures. This could have profound implications for early intervention, potentially improving spatial memory and problem-solving abilities in these patients. A quick MEG exam could thus provide a valuable tool for enhancing patient care while reducing healthcare costs.

Future Directions

As researchers continue to explore the use of MEG and HFOs in the diagnosis and treatment of Alzheimer’s, this discovery represents a significant step forward. The ability to easily screen for epileptic activity using a non-invasive, quick procedure could dramatically impact patient outcomes and healthcare practices.

Conclusion

The breakthrough by the UCLA Health team marks a pivotal moment in Alzheimer’s research. The identification and management of seizure activity could lead to improved care and quality of life for many patients. As this technology continues to develop and become more widely accessible, it holds the potential to transform the landscape of Alzheimer’s treatment.

We invite you to share your thoughts on this groundbreaking discovery. Join the conversation by leaving a comment below, subscribing to our newsletter for future updates, or sharing this article on your social media channels.